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Hemophagocytic lymphohistiocytosis is a hyperinflammatory syndrome defined by clinical and laboratory criteria.
Current criteria were created to identify patients with familial hemophagocytic lmyphohistiocytosis in immediate
need of immunosuppressive therapy. However, these criteria also identify patients with infection-associated hemo-
phagocytic inflammatory states lacking genetic defects typically predisposing to hemophagocytic lymphohistiocyto-
sis. These patients include those with primary immunodeficiencies, in whom the pathogenesis of the inflammatory
syndrome may be distinctive and aggressive immunosuppression is contraindicated. To better characterize hemo-
phagocytic inflammation associated with immunodeficiencies, we combined an international survey with a literature
search and identified 63 patients with primary immunodeficiencies other than cytotoxicity defects or X-linked lym-
phoproliferative disorders, presenting with conditions fulfilling current criteria for hemophagocytic lymphohistiocy-
tosis. Twelve patients had severe combined immunodeficiency with <100/μL T cells, 18 had partial T-cell deficien-
cies; episodes of hemophagocytic lymphohistiocytosis were mostly associated with viral infections. Twenty-two
patients had chronic granulomatous disease with hemophagocytic episodes mainly associated with bacterial infec-
tions. Compared to patients with cytotoxicity defects, patients with T-cell deficiencies had lower levels of soluble
CD25 and higher ferritin concentrations. Other criteria for hemophagocytoc lymphohistiocytosis were not discrim-
inative. Thus: (i) a hemophagocytic inflammatory syndrome fulfilling criteria for hemophagocytic lymphohistiocy-
tosis can be the initial manifestation of primary immunodeficiencies; (ii) this syndrome can develop despite severe
deficiency of T and NK cells, implying that the pathophysiology is distinct and not appropriately described as “lym-
pho”-histiocytosis in these patients; and (iii) current criteria for hemophagocytoc lymphohistiocytosis are insufficient
to differentiate hemophagocytic inflammatory syndromes with different pathogeneses. This is important because of
implications for therapy, in particular for protocols targeting T cells.  
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ABSTRACT
Introduction
Hemophagocytic lymphohistiocytosis (HLH) is a life-
threatening hyperinflammatory syndrome. The term was
initially coined based on histomorphological features.1
The hereditary disorders, of which the HLH syndrome is
the defining clinical manifestation, have been associated
with autosomal recessive mutations in genes encoding
perforin (familial hemophagocytic lymphohistiocytosis,
FHL-2) and a group of proteins required for secretion of
perforin-containing cytotoxic granules (FHL 3-5, Griscelli
syndrome type 2 and Chediak-Higashi syndrome).1 HLH
is also a frequent manifestation of some defined genetic
disorders of Epstein-Barr virus (EBV) susceptibility, e.g. X-
linked lymphoproliferative syndromes (XLP1 and XLP2).2
Impaired lymphocyte cytotoxicity with highly activated,
but inefficient T cells are the main pathogenic factors in
the former group of disorders,3 while the pathophysiolog-
ical basis of HLH in XLP and other syndromes of EBV sus-
ceptibility is less well understood. 
As defined by the Histiocyte Society, the diagnosis of
HLH syndrome is based on fulfillment of five out of eight
clinical and laboratory parameters or a molecular diagno-
sis of a disease conferring a high risk of developing HLH.
These criteria have been useful for the identification of
patients with genetic defects in lymphocyte cytotoxicity.
However, they are also fulfilled by a range of other
patients presenting with hemophagocytic inflammatory
disease, but normal cytotoxicity. Thus, the HLH syn-
drome can manifest in the context of severe infections
including viral infections or sepsis/systemic inflammatory
response syndrome, autoimmune and autoinflammatory
diseases or malignancies such as lymphomas.4-6 These dis-
ease states are frequently summarized as “secondary
HLH”, “acquired HLH” or “macrophage activation syn-
drome”. Affected patients usually present with clinical and
laboratory manifestations that cannot be readily distin-
guished from those observed in patients with defects in
cytotoxicity.4-6 However, the fact that defective cytotoxic-
ity cannot be consistently found in such patients suggests
that the pathophysiological pathways leading to HLH syn-
drome may differ between different groups of patients.5
Current treatment guidelines based on the HLH-2004
study of the Histiocyte Society recommend that HLH-
directed therapy should be strongly considered if five out
of eight diagnostic criteria are fulfilled, irrespective of
whether they occur in the presence of defects in lympho-
cyte cytotoxicity or in other forms of the disease.7 While
there is no doubt that this therapy can be life-saving in
patients with FHL and many instances of infection-associ-
ated HLH,8 less intensive anti-inflammatory treatment is
frequently sufficient for patients with other forms of
hemophagocytic inflammatory disease and aggressive
immunosuppression may even be contraindicated.1,9
Moreover, more specific therapies for HLH targeting T
cells9 or interferon-γ3,10 are undergoing prospective evalua-
tion. Potential differences in the pathogenic events leading
to HLH syndrome are, therefore, becoming increasingly
relevant. 
One well-defined group of patients in whom the HLH
syndrome has been described, are patients with primary
immunodeficiencies (PID) other than FHL or XLP. Single
cases or small case series of HLH syndrome have been
reported in a variety of PID, and the clinical presentation
of some of these cases has recently been summarized.11
However, a multicenter systematic analysis of the clinical
and laboratory features of HLH syndrome in these
patients in comparison to HLH associated with defects in
lymphocyte cytotoxicity has not been performed. We rea-
soned that such an analysis might offer the opportunity to
identify parameters for differential diagnosis, facilitating
early identification of patients with hemophagocytic
inflammatory disease in whom aggressive immunosup-
pressive therapy may be contraindicated. Furthermore,
since PID provide an excellent possibility to study the role
of constitutional immunological abnormalities in
immunopathological conditions, we expected to gain
some insights relevant to the pathogenesis of HLH syn-
drome.
Methods 
Recruitment of patients
To identify patients with PID other than disorders of cytotoxic-
ity or XLP and a clinical presentation with a disease state fulfilling
the HLH-2004 criteria for HLH, we performed a survey among
centers involved in the diagnosis and treatment of PID and/or
HLH through the Histiocyte Society, the European Society of
Blood and Bone Marrow Transplantation’s Inborn Errors Working
Party and the German Society for Pediatric Oncology and
Hematology. These data were supplemented by a literature
review based on a PubMed search for "hemophagocytic lympho-
histiocytosis", "macrophage activation syndrome", and "immuno -
deficiency" or individual immunodeficiencies such as “chronic
granulomatous disease” (CGD) up to December 31st, 2014. All
cases were reviewed by SFNB and SE. Patients were included if
they fulfilled the following criteria: (i) genetic or clinical diagnosis
of a defined PID as classified by the International Union of
Immunological Societies Expert Committee for Primary
Immunodeficiency (IUIS) except for genetic defects in cytotoxici-
ty, XLP1 or XLP2;12 and (ii) presence of at least five out of eight
diagnostic criteria for HLH according to the HLH-2004 criteria.7
These eight criteria are: (i) fever; (ii) splenomegaly; (iii) cytopenia
of two or more cell lines (hemoglobin ≤90 g/L, platelets
≤100x109/L, neutrophils ≤1x109/L); (iv) hypofibrinogenemia (≤1.5
g/L) or hypertriglyceridemia (≥265 mg/dL); (v) hyperferritinemia
(≥500 ng/mL); (vi) increased level of soluble CD25 (sCD25, ≥2400
U/mL); (vii) evidence of hemophagocytosis; and (viii) decreased or
absent NK cell cytotoxicity. From all patients, we recorded the
underlying immunodeficiency diagnosis, the individual diagnostic
criteria for HLH, associated infections, treatment and outcome of
the HLH episode and whether or not HLH developed at/before or
after the diagnosis of PID.
Control groups
Laboratory values of these patients were compared to those
observed in a cohort of patients with active “primary” HLH (FHL
2-5; n=90) and a cohort of patients with infection-associated “sec-
ondary” HLH (I-HLH; n=40) without another known underlying
disease such as malignancy, rheumatological or metabolic disease
from the German HLH registry. This registry collects clinical,
immunological and genetic information on patients referred for
evaluation for HLH from German speaking countries. Around 100
patients are referred each year and around 60 of these fulfill the
diagnostic criteria for HLH. The group of patients with I-HLH con-
sisted of patients who: (i) fulfilled at least five of the eight diagnos-
tic criteria for HLH; (ii) had an infection proven by positive poly-
merase chain reaction or unequivocal serology at the time of mani -
festing HLH; (iii) did not have either a mutation in HLH-related
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genes (if investigated) or another obvious underlying genetic dis-
ease or a positive family history for HLH; and (iv) had not had a
disease relapse within at least 12 months after the HLH manifes-
tation.13 About 20% of the patients in this group were thoroughly
evaluated for mutations in HLH-causing genes because of ambigu-
ous or abnormal results in the functional analysis. 
Statistical analysis
Statistical analysis was performed with GraphPad InStat soft-
ware version 6.05. First we calculated the natural logarithms of the
means of sCD25, ferritin, fibrinogen, and triglyceride levels.
Differences between group means were then evaluated with one-
way analysis of variance with a post-hoc Tukey test. Differences
were considered statistically significant at P values <0.05.
Ethics
The study was approved by the ethics committee of the Albert-
Ludwigs-Universität Freiburg (AK28/14) and conducted according
to the Declaration of Helsinki.
Results
Patients and sequence of diagnosis
We identified 28 patients with PID other than defects in
cytotoxicity or XLP fulfilling the HLH-2004 diagnostic cri-
teria through the survey and found 30 publications
describing another 35 cases (Table 1).14-43 Six of the 18 cases
recently summarized by Faitelson11 were not included in
S.FN Bode et al.
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Table 1. Cohort of patients with HLH syndrome in the context of primary immunodeficiencies. 
Patient        PID (affected gene)           Age at  HLH at/before       Associated                                        HLH directed              Outcome        Reference
number                                                 HLH [y] PID diagnosis       infection                                           therapy                                                     
SCID                                                                                                                                                                                                                                                                         
1                       SCID (ILR2G)                            0.13                 +                    Rhinovirus, Enterobacter                       IVIG, CsA                               √                        14
2                       SCID (ILR2G)                            0.17                 +                    Gram-negative sepsis                             steroids, eto                         †                         15
3                       SCID (ILR2G)                             0.3                   +                    M. tuberculosis                                         IVIG                                        √                          
4                       SCID (ILR2G)                             0.3                   +                    CMV                                                             steroids, eto                        √                          
5                       SCID (ILR2G)                             0.3                   -                     P. aeruginosa                                             IVIG                                         †                         16
6                       SCID (RAG-1)                              1                     -                     Adenovirus                                                 -                                                †                           
7                       SCID (RAG-1)                             1.5                   +                    Adenovirus                                                 steroids                                 †                           
8                       SCID (IL7RA)                            0.21                 +                    EBV                                                              HLH 94                                   †                           
9                       SCID (CD3E)                              0.5                   +                    Adenovirus                                                 -                                                †                           
10                    SCID (T-, B-, NK+)                   0.3                   ?                     CMV                                                             IVIG                                         †                           
11                    SCID (T-, B+, NK+)                 0.42                 +                    EBV                                                              steroids, eto                         †                         17
12                    SCID (undefined)                     0.4                   +                    PJ, CMV                                                       -                                                √                           
CID
13                    CID (clinical Omenn)*            1.3                   -                     St. maltophilia, Alternaria                      -                                                †                           
14                    CID (RAG-1)*                              1                    +                    -                                                                    -                                               √                          
15                    22q11                                            0.3                   -                     -                                                                    -                                                ?                            
16                    22q11                                            1.1                   -                     -                                                                    HLH-1994                               †                         18
17                    22q11                                            1.5                   -                     EBV                                                              IVIG, steroids                      √                           
18                    22q11                                            5.6                   -                     EBV                                                              HLH-1994                               †                         19
19                    WAS                                              0.3                   -                     EBV                                                              HLH-1994                               †                         20
20                    WAS                                              0.6                   +                    CMV                                                             IVIG, steroids                      √                        21
21                    WAS                                              1.3                   -                     CMV                                                             IVIG, steroids                       †                           
22                    WAS                                              1.5                   +                    CMV                                                             -                                               √                          
23                    Ataxia telangiectasia                17.3                  -                     EBV, parvovirus                                         steroids, CsA                        †                           
24                    DKC1                                              4                    +                    EBV                                                              -                                                √                           
25                    CD 27                                            1.5                   +                    EBV                                                              IVIG, steroids, ritux,           √                      22, 23
26                    CD 27                                            1.5                   +                    EBV                                                              ritux, HLH-2004                   √                     22, 23
27                    ITK                                                  5                    +                    EBV                                                              steroids, ritux, eto              †                         24
28                    CID (predominantly T-)          0.17                 +                    CMV                                                             -                                                †                         25
29                    CID (undefined)                       0.5                   +                    Noro/Rotavirus                                         IVIG                                         √                           
30                    CID (undefined)                       4.4                   -                     -                                                                    HLH-1994/2004                     √                           
CGD                                                                                                                                                                                                                                                                          
31                    CGD (p91)                                 0.17                 +                    C. lusitaniae, MRSA                                 IVIG, steroids                      √                          
32                    CGD (p91)                                 0.17                 +                    C. lusitaniae                                             IVIG, steroids, CsA              √                         26
33                    CGD (p91)                                  0.9                   +                    B. cepacia, HHV-6                                    steroids                                 √                        27
continued on the next page
this analysis because of incomplete information on our
inclusion criteria as were ten cases identified by either the
survey or the literature review. In total, we identified 63
patients with PID and an HLH syndrome. The median age
at diagnosis of the HLH syndrome was 1.5 years (range
0.13-34 years). Notably, an HLH syndrome was the initial
presentation leading to diagnosis of the underlying PID in
36 patients, whereas 25 patients developed HLH after the
diagnosis of PID had been established; for two patients
this information was not available. 
Spectrum of primary immunodeficiencies presenting
with hemophagocytic lymphohistiocytosis syndrome
More than 80% of patients had two main groups of PID.
Thirty patients had combined immunodeficiencies (CID).
More specifically, 12 patients had SCID with a variety of
molecular causes (Table 1). Interestingly, in nine of these
12 patients, the HLH syndrome developed in the first
months of life, at or before the diagnosis of the immunod-
eficiency. Eighteen patients had other well-characterized
CID affecting T-cell development or function, including
“atypical” SCID44 with significant numbers of autologous
T cells (n=2), 22q11 deletion syndrome (n=4), Wiskott-
Aldrich syndrome (n=4), ataxia telangiectasia (n=1) and
dyskeratosis congenita (n=1). Two patients had CD27
deficiency and one had ITK deficiency, conditions that
have previously been associated with poor control of EBV
infection (Table 1).45,46 The second main group consisted of
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34                    CGD (p91)                                    2                     -                     -                                                                    steroids                                 √                        28
35                    CGD (p91)                                    2                    +                    P. spp., Salmonella spp.                           steroids, CsA                        √                         29
36                    CGD (p91)                                    3                     -                     B. cepacia                                                  IVIG, steroids                      √                         30
37                    CGD (p91)                                  3.5                   -                     -                                                                    steroids                                 √                          
38                    CGD (p91)                                  3.5                   +                    B. cepacia, St. maltophilia                    HLH-2004                               †                         31
39                    CGD (p91)                                   15                    -                     Leishmania spp.                                       -                                                √                         32
40                    CGD (p91)                                   18                    -                     Leishmania spp.                                       -                                                †                         32
41                    CGD (p91)                                   24                    -                     Leishmania spp.                                       IVIG, steroids                      √                           
42                    CGD (p91)                                   26                    -                     Leishmania spp.                                       IVIG, steroids                      √                           
43                    CGD (p91)                                   34                    -                     Leishmania spp.                                       IVIG, steroids                      √                           
44                    CGD (p47)                                  2.5                   +                    B. cepacia, EBV                                        steroids, CsA                       √                          
45                    CGD (p47)                                    9                     ?                     Leishmania spp.                                       IVIG                                         √                         32
46                    CGD (p22)                                  0.8                   +                    C. parapsilopsis                                        steroids                                 √                           
47                    CGD (p22)                                   29                    -                     B. cepacia                                                  steroids, CsA                        √                         33
48                    CGD (DHR)                                1.4                   +                    B. cepacia                                                  IVIG                                         √                         34
49                    CGD (DHR)                                3.7                   +                    B.cepacia                                                   IVIG, steroids                      √                           
50                    CGD (clinical)                             6                     -                     E. cloacae, S. epidermidis                      IVIG, steroids                       √                         35
51                    CGD (clinical)                             7                     -                     Aspergillus spp.                                        IVIG, steroids                       √                         35
52                    CGD (clinical)                            12                    -                     -                                                                    IVIG, steroids                       √                         35
Others                                                                                                                                                                                                                                                                      
53                    XLA (BTK)                                   0.7                   +                    Adenovirus                                                 IVIG, HLH-2004                     †                         36
54                    XLA (BTK)                                    3                    +                    Adenovirus                                                 IVIG                                         √                         36
55                    ALPS (FAS)                                   3                    +                    -                                                                    IVIG, steroids                      √                         37
56                    ALPS (FAS)                                   6                    +                    -                                                                    HLH-2004                               √                         38
57                    Cyclic neutropenia                    19                    -                     EBV                                                              IVIG, steroids                        ?                            
58                    NEMO                                          0.2                   +                    K. pneumoniae                                          IVIG                                        √                        39
59                    STAT1 (GOF)                             0.15                 +                    -                                                                    steroids                                 †                           
60                    TRAPS                                           11                   +                    -                                                                    HLH-2004                               √                         40
61                    FMF                                                4                    +                    -                                                                    steroids, CsA                        √                         41
62                    FMF                                               11                    -                     A. baumanii                                               IVIG, steroids, CsA              †                         42
63                    NLRC4                                            7                    +                    -                                                                    steroids                                 √                         43
√: alive; †:  deceased; n.a.:  not available;  A:  Acinetobacter; ALPS:  autoimmune lymphoproliferative syndrome; B:  Burkholderia; C:  Candida; CGD:  chronic granulomatous disease;
CID:  combined immunodeficiency; GOF:  gain of function; CMV:  cytomegalovirus; CsA:  cyclosporine A; DKC:  dyskeratosis congenita; E:  Enterobacter; EBV:  Epstein-Barr virus;
FMF:  familial Mediterranean fever; IVIG:  intravenous immunoglobulins; M:  Mycobacterium; MRSA:  methicillin-resistant Staphylococcus aureus; P:  Pseudomonas; PJ:
Pneumocystis jirovecii; ritux:  rituximab; S:  Staphylococcus; SCT:  stem cell transplantation; spp.:  species; St:  Stenotrophomonas; TRAPS: tumor necrosis factor-1 receptor associ-
ated periodic syndrome; eto:  etoposide; WAS:  Wiskott Aldrich syndrome; XLA:  X-linked agammaglobulinemia. *:  these patients did not qualify as SCID as they had significant resid-
ual autologous T, B, and NK cells.
Patient n.     PID (affected gene)           Age at  HLH at/before       Associated                                        HLH directed              Outcome        Reference
                                                              HLH [y] PID dia-gnosis      infection                                           therapy                                                     
continued from the previuos page
22 patients with chronic granulomatous disease (CGD)
(Table 1). Most of these patients presented with HLH syn-
drome beyond the first year of life, some in adulthood. In
nine of the younger patients (<4 years), the HLH syn-
drome developed at or before the diagnosis of CGD. Only
11 patients had other PID, including antibody deficiencies
(n=2), diseases of immune dysregulation (n=2), other con-
genital defects of phagocytes (n=1), defects in innate
immunity (n=2), or autoinflammatory disorders (n=4)
(Table 1). 
Infections associated with hemophagocytic 
lymphohistiocytosis syndrome in patients with primary
immunodeficiencies
In 50/63 patients (79%), the HLH syndrome was associ-
ated with an infection. In SCID and CID patients, it was
mainly associated with viral infections. Ten of 30 (33%)
patients had EBV infection, seven had cytomegalovirus
infection, three had infections with adenovirus and two
had infections with other gastrointestinal or respiratory
viruses. In contrast, in only two of the 22 (9%) CGD
patients was the HLH syndrome associated with a viral
infection and in both cases an additional bacterial infec-
tion was diagnosed. The main infectious agents in the
group of CGD patients were Burkholderia cepacia (n=7),
Leishmania spp. (n=6), and fungi (n=4). In the group of 11
patients with other PID, the HLH syndrome was associat-
ed with a viral infection in three and a bacterial infection
in two patients (Table 1). 
Lymphocyte compartment in patients with severe 
combined immunodeficiency
Since activated T cells and possibly NK cells are regard-
ed as major effectors in the pathogenesis of FHL,1,3 we had
a closer look at the lymphocyte compartment in SCID
patients. Interestingly, all SCID patients had fewer than
100 T cells/μL (including 9 patients with fewer than 20 T
cells/μL) (Table 2). Four patients had been analyzed for
maternal T cells, which were detected at low numbers in
two of them. Three patients also had 10 or fewer NK
cells/μL. The number of B cells was more variable.  
Diagnostic parameters in patients with primary immun-
odeficiencies presenting with hemophagocytic lympho-
histiocytosis syndrome
Information on all eight HLH-2004 diagnostic criteria
was only available for seven patients, while seven criteria
were reported in an additional 15 patients. Information
was usually lacking on sCD25 (reported in 23/63 patients,
36%) or NK cell cytotoxicity (reported in 19/63 patients,
30%). On the other hand, all patients fulfilled at least five
diagnostic criteria. In 36 patients (57%), all of the five to
eight reported criteria were positive. When looking at
individual criteria, no particular pattern emerged that was
characteristic for PID or PID subgroups. Of the patients
for whom information on these criteria was available,
98% had fever, 91% had splenomegaly, 91% had cytope-
nias, 80% had elevated triglycerides, 75% had low fib-
rinogen, 100% had elevated ferritin, 82% had elevated
sCD25 and 63% had low or absent NK cell cytotoxicity. 
We then quantitatively compared the laboratory values
of patients with T-cell deficiencies and CGD to those
obtained in a cohort of patients with FHL (n=90) and a
cohort of patients with infection-triggered "secondary"
HLH (I-HLH) (n=40). The most significant differences
were observed in the serum concentrations of soluble
interleukin-2 receptor (sCD25) (Figure 1A, Table 3).
Patients with T-cell deficiencies had significantly lower
values than those observed in patients with FHL (mean:
T-cell deficiencies:  5290 U/mL, FHL: 23074 U/mL;
P<0.0001). Notably, levels were also lower in patients
with I-HLH than in patients with FHL. In contrast, the
concentrations of ferritin were higher in the patients with
T-cell deficiencies than in the other three groups of
patients, but only significantly higher than those in the
FHL patients (P<0.05; mean: T-cell deficiencies: 64808
ng/mL, FHL: 10154 ng/mL, I-HLH: 8359 ng/mL, CGD
8819 ng/mL; Figure 1B). These differences were even
more obvious, when the ratio of ferritin/sCD25 was
determined, which was significantly higher in patients
with T-cell deficiencies than in FHL, I-HLH, and CGD
patients (mean: T-cell deficiencies: 14.18, FHL: 0.37, I-
S.FN Bode et al.
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Table 2. Lymphocyte subsets in patients with SCID and hemophagocytic inflammatory syndrome. 
Patient CD3 T cells/μL CD4+ T cells/μL CD8+ T cells/μL NK cells/μL B cells/μL Materno-fetal
number transfusion
1 30 0 20 0 0 +
2 18 10 8 32 85 n.a.
3 0 0 0 9 1178 -
4 30 n.a. n.a. 95 0 +
5 18 16 0 10 990 n.a.
6 14 9 5 59 5 n.a.
7 84 26 57 2143 466 -
8 20 <10 <20 n.a. < 20 n.a.
9 0 0 0 45 959 n.a.
10 4 2 1 146 5 n.a.
11 0 0 0 n.a.* 1920 n.a.
12 16 16 <1 296 1574 n.a.
n.a.: no data available. *: NK+ according to 17.
HLH in primary immunodeficiencies
haematologica | 2015; 100(7) 983
Figure 1. (A) Serum sCD25 levels in patients with SCID/CID, FHL, I-HLH (infection triggered “secondary” HLH), and CGD. (B) Serum ferritin lev-
els in SCID/CID, FHL, I-HLH, and CGD patients. (C) Ratio of ferritin/sCD25 in SCID/CID, FHL, I-HLH, and CGD patients.  *P<0.05. **P<0.01.
The dotted line indicates the cut-off value according to the HLH diagnostic criteria. The bars indicate means ± standard deviation.
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HLH: 0.48, CGD: 0.90; Figure 1C; see figure for P-values).
Apart from a significant difference in fibrinogen levels
between FHL and I-HLH patients, no relevant differences
were observed in the other HLH-defining parameters (fib-
rinogen: mean FHL: 1.218 g/L, I-HLH: 1.869 g/L; P<0.05;
Figure 2).
Treatment and outcome
The patients received a wide range of HLH-directed
treatment regimens, including corticosteroids alone or in
combination with intravenous immunoglobulins,
cyclosporine or rituximab (Table 1). Etoposide-based ther-
apy was given to 14 patients, including ten patients with
T-cell deficiencies, six of whom received their PID diag-
nosis during or after the episode of HLH syndrome. Only
one patient with CGD received etoposide-based therapy.
Thirty-nine (65%) of 60 patients with reported outcome
survived the episode of HLH syndrome. Of note, only
four of 12 SCID patients and nine of 18 patients with CID
and reported outcome survived, which contrasted with
20 of 22 CGD patients.
Discussion
This study identified 63 patients with PID other than
genetic disorders of cytotoxicity or XLP, who fulfilled the
current clinical criteria for HLH. In 36 of them, this HLH
syndrome was the initial manifestation before or at the
diagnosis of PID. PID other than disorders of cytotoxicity
or XLP are, therefore, a relevant differential diagnosis in
patients presenting with the clinical picture of HLH syn-
drome. 
While many PID may predispose to an infection-trig-
gered HLH syndrome, this was largely restricted to two
groups in this cohort: patients with T-cell deficiencies,
who are susceptible to a broad range of infections, viral
infections in particular, and patients with CGD, who are
susceptible to a narrower spectrum of bacterial and oppor-
tunistic, but not viral, infections. Infections associated
with the HLH syndrome in PID patients reflected this spe-
cific susceptibility, compatible with the notion that uncon-
trolled pathogen replication is a major risk factor for this
hyperinflammatory syndrome. However, while HLH syn-
drome was observed in a relevant number of CGD
patients, it was not reported in other congenital defects in
phagocytes and only rarely in other defects in innate
immunity. It is, therefore, tempting to hypothesize that
HLH syndrome in CGD may not only reflect impaired
infection control, but also a genetic predisposition to
hyperinflammation. Colitis and other inflammatory organ
pathologies associated with granuloma formation are
well-known complications in this disease,47 which were
recently linked to autophagic dysfunction.48 This apparent
association of impaired autophagy with HLH syndrome
warrants future investigation. It should be noted that the
design of our study did not allow us to exclude a potential
contribution of monoallelic mutations or polymorphisms
in FHL-associated genes to the manifestation of HLH in all
patients. Nevertheless, at least seven patients were tested
for all known genes associated with FHL and in a number
of other patients individual genes were sequenced with-
out detection of relevant mutations or polymorphisms
such as perforin A91V. 
An imbalance between viral control and immune activa-
tion is thought to be an important determinant of the HLH
syndrome associated with viral infections (such as EBV)
and in a proportion of patients with FHL. This is support-
ed by evidence from mouse models.3,49 In these models,
hyperactive T cells are a key factor in disease pathogene-
sis.2,50 It was, therefore, surprising that, paradoxically, a sig-
nificant number of patients with T-cell deficiencies,
including several patients without detectable circulating T
cells, developed the HLH syndrome. Notably, at least
three T-cell deficient X-SCID patients also had ≤10/μL NK
cells, rendering it unlikely that hyperactivated NK cells
replaced T cells as a pathogenic factor in these cases. This
is further supported by a significantly lower level of
sCD25 in this group of patients compared to patients with
FHL or I-HLH. These observations suggest that the HLH
syndrome can develop despite severe deficiency of T and
NK cells, two main effectors implicated in “primary” HLH.
Due to this absence of T and NK cells, the term hemo-
phagocytic “lympho”-histiocytosis appears inappropriate to
describe the “HLH-like” disease in SCID patients. It seems
likely that in these patients activation of macrophages and
the associated cytokine release proceed independently of
lymphocytes. The term "hemophagocytic inflammatory
syndrome" (HIS) may, therefore, better describe this con-
dition. Although not addressed in this study, it is possible
that such a distinction may also be relevant for some other
disease states currently classified as “secondary” HLH. 
The current HLH-2004 criteria were insufficient for this
discrimination. Neither the number nor the combination
of HLH-2004 criteria fulfilled in patients with PID and HIS
was different from what is usually observed in “primary”
or infection-associated “secondary” HLH. It should be
stated that in most PID patients summarized in this study,
not all eight criteria were documented. However, sCD25
is frequently also not determined in many patients with
familial HLH and in most centers NK cell cytotoxicity test-
ing has been replaced by intracellular protein and degran-
ulation studies.51 The only notable differences between
the two groups were the relatively low sCD25 levels and
high ferritin levels in most patients with T-cell deficien-
cies. This most likely reflects the lack of T cells in SCID
S.FN Bode et al.
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Table 3. HLH diagnostic criteria in patients with PID and hemophagocytic inflammatory syndrome. 
Patient Fever Splenomegaly Cytopenia Triglycerides Fibrinogen Hemophago Ferritin sCD25 NK HLH 
number 2/3 cell lines (mg/dL) (g/L) -cytosis (ng/mL) (U/mL) cytotoxicity criteria
SCID
1 + - + n.a. n.a. + 872 9016 n.a. 5/5
2 + + + 374 0.2 + 1774 n.a. n.a. 6/6
3 + + + 486 n.a. + 5866 n.a. n.a. 6/6
4 + + - 337 1.7 n.a. 22000 4349 reduced 6/6
5 + + - 524 0.11 + 9973 n.a. n.a. 5/6
6 + + + 160 0.89 + 77000 1365 n.a. 6/7
7 + - + 440 0.93 + 3133 890 normal 5/7
8 + + + 156 1.2 + 3474 n.a. n.a. 6/6
9 + - + n.a. 0.98 + >1.000.000 3078 n.a. 6/7
10 + + + 379 2.92 + 4400 1509 n.a. 6/7
11 + + + 241 5.02 + 5866 n.a. n.a. 5/6
12 + + - 367 1.96 n.a. 73100 3635 n.a. 5/6
CID
13 + + + 389 1.4 n.a. 2066 n.a. n.a. 5/5
14 + + + n.a. <1.5 n.a. >500 n.a. n.a. 5/5
15 + + + >265 n.a. n.a. n.a. 4803 n.a. 5/5
16 + + + 693 0.8 + 10854 8540 reduced 8/8
17 + + + 575 0.5 + 4000 n.a. n.a. 6/6
18 + + + >265 <1.5 + >500 n.a. n.a. 6/6
19 + + + 315 1.4 + 169195 n.a. reduced 7/7
20 + + + 245 2.27 - 785 12080 n.a. 5/7
21 + - + 310 0.9 + 2650 n.a. n.a. 5/6
22 + + + 938 1.2 - 1320 n.a. normal 5/7
23 + + + 319 1.4 + 35000 12400 n.a. 7/7
24 + + + 319 1.6 - 2058 n.a. reduced 5/7
25 + + + >265 <1.5 - >500 n.a. reduced 6/7
26 + n.a. + n.a. <1.5 n.a. >500 n.a. reduced 5/5
27 + + + 298 0.2 + >7500 n.a. n.a. 6/6
28 + + + n.a. n.a. + >10000 n.a. n.a. 5/5
29 + + - 482 0.7 + 90000 1815 absent 6/8
30 + + + 411 >1.5 + >20000 n.a. reduced 7/7
continued on the next page
and the low T-cell counts and/or impaired T-cell function
in CID patients. Furthermore, the ratio of ferritin to
sCD25 heightened these differences and appears to be a
useful measure, as has previously been suggested in lym-
phoma-associated HLH.52 Our (admittedly limited) data
suggest that a ferritin:sCD25 ratio of ≥3 should be viewed
as suggestive of SCID/CID in an infant with the HLH syn-
drome. Because current understanding of HLH pathogen-
esis suggests that “overactivated” T cells exuberantly
recruit innate effectors (macrophages) to drive HLH dis-
ease manifestations,3,53 these findings suggest that uncon-
trolled viral infections in the context of SCID/CID may
circumvent the typical HLH pathogenesis.  It remains to
be shown whether such an alternative pathophysiology
may also be relevant for some cases of infection-associat-
ed or rheumatologic “secondary” HLH in apparently
immunocompetent individuals. In this context it is note-
worthy that sCD25 levels were also significantly lower in
patients with infection-associated “secondary” HLH than
in patients with FHL, though this may simply illustrate the
propensity towards T-cell ‘overactivation’ in individuals
with defective cytotoxic function.  
HLH in primary immunodeficiencies
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Patient Fever Splenomegaly Cytopenia Triglycerides Fibrinogen Hemophago Ferritin sCD25 NK HLH 
number 2/3 cell lines (mg/dL) (g/L) -cytosis (ng/mL) (U/mL) cytotoxicity criteria
CGD
31 + + + 276 1.1 n.a. 2039 13483 normal 6/7
32 + + + n.a. 0.8 + 11783 17035 n.a. 7/7
33 + + + n.a. 2.4 + 16800 n.a. n.a. 5/6
34 + + + n.a. n.a. n.a. 14838 n.a. n.a. 5/5
35 + + + >265 n.a. + >500 n.a. n.a. 6/6
36 + + + 395 1.79 n.a. 750 n.a. n.a. 5/5
37 + + + >265 1.3 - 2500 n.a. n.a. 5/6
38 + + + 280 0.7 - 6539 18115 n.a. 6/7
39 + + + >265 <1.5 + n.a. n.a. n.a. 5/5
40 + + + >265 <1.5 + >500 n.a. n.a. 6/6
41 + + + 454 0.98 + 1192 n.a. n.a. 6/6
42 + + + n.a. 0.95 + 39734 n.a. n.a. 6/6
43 + + + n.a. n.a. + 2378 n.a. n.a. 5/5
44 + + + >265 n.a. n.a. >500 n.a. n.a. 5/5
45 + + + >265 n.a. + >500 n.a. n.a. 6/6
46 + + + 306 2.07 - 546 4097 reduced 7/8
47 + + - n.a. 4.3 + 820 >2400 n.a. 5/6
48 + + + 266 n.a. + n.a. n.a. n.a. 5/5
49 + + + 166 0.6 n.a. 22919 n.a. n.a. 5/5
50 + + + 134 <0.5 + 523 n.a. n.a. 6/6
51 + + + 438 1.26 + n.a. n.a. n.a. 5/5
52 + + + 147 3.69 + 8930 2816 n.a. 6/7
Others
53 + - + 138 0.87 + 54399 n.a. absent 6/7
54 + - + 287 1.25 + 19886 >2400 reduced 7/8
55 + + + 350 n.a. - 2760 15570 n.a. 6/6
56 - + + 292 n.a. - 809 18651 normal 5/7
57 + + + >265 <1.5 n.a. >500 >7500 n.a. 6/6
58 + + + n.a. 1 + 27750 n.a. reduced 7/7
59 + + + >265 <1.5 + >500 n.a. n.a. 6/6
60 + + n.a. n.a. n.a. + 8030 >2400 normal 5/6
61 + + + n.a. 1.3 + n.a. n.a. normal 5/6
62 + + + 261 n.a. + 672 n.a. n.a. 5/6
63 + + + >265 n.a. n.a. >500 n.a. normal 5/6
n.a.: no data available. Parameters fulfilling the HLH diagnostic criteria are indicated in bold. The last column indicates the number of abnormal criteria relative to the number of
criteria investigated/reported.
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Disease classifications should be based on pathophysio-
logical knowledge with the goal of facilitating the best
treatment decisions for affected patients. The observations
of this study further illustrate that the current diagnostic
HLH criteria defined by the HLH-2004 protocol describe a
common clinical and biological endpoint resulting from
different conditions and pathways of pathogenesis. We
think that there are good arguments to reserve the term
hemophagocytic “lympho”-histiocytosis (HLH) to disease
states that are associated with a predominantly T-cell-
mediated immunopathogenesis, including “primary” HLH
and some cases of infection-associated “secondary” HLH.
In these cases, etoposide-based protocols or T-cell-directed
immune therapy, e.g. based on antithymocyte globulin9 or
alemtuzumab,54 are indicated and can be highly effective.
In contrast, strong immunosuppressive therapy may not
always be appropriate and may even be harmful for other
groups of patients, especially those with PID other than
FHL or XLP. In this study, we propose the provisional term
“hemophagocytic inflammatory syndrome” (HIS) to classi-
fy these patients, in whom the intensity of immunosup-
pressive treatment needs to be carefully adapted to the
underlying immunodeficiency and ongoing infections. 
HIS could be an umbrella term for different diseases cur-
rently referred to as “primary” or “secondary” forms of
HLH or macrophage activation syndrome. According to
this concept, HLH would be one form of HIS. We propose
maintaining the term “hemophagocytic” despite the fact
that not all patients fulfill this criterion (41/50 in our study)
for the following reasons: (i) the probability of detecting
hemophagocytosis depends on the time point of the
analysis, which in many cases is performed only once; (ii)
the element of activated phagocytes producing cytokines
is likely to be essential for all forms of HIS; (iii) keeping
this element will keep the term searchable in the literature
and maintain awareness of physicians that this is a serious
condition; and (iv) the term hyperinflammatory alone is
poorly discriminative with regards to other inflammatory
conditions. It is important to note that these considera-
tions are suggestions and any change in nomenclature
should be legitimated by the Histiocyte Society, which is
currently engaged in revising the terminology for this
group of diseases.
It is an obvious difficulty of current nomenclature that a
single clinical scenario (e.g. EBV-associated HLH in an
infant) could exemplify HLH associated with a defect in
lymphocyte cytotoxicity, a T-cell-driven “secondary”
HLH, or a T/NK-cell-independent HIS in a SCID patient,
each with a potentially different pathophysiology and a
common phenotypic endpoint. It is thus important to
remember that the HLH syndrome itself never represents
a complete diagnosis. It will be an important challenge to
produce diagnostic criteria that can help to separate etio-
logically different conditions. The ratio of ferritin to
sCD25 may represent one such criterion, but new bio-
markers specifically reflecting the individual pathophysio-
logical pathway leading to the inflammatory disease state
of the HLH syndrome are needed. It will be of particular
interest to evaluate whether markers of immune cell acti-
vation in addition to cytokine patterns may more specifi-
cally reflect disease pathogenesis.
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Figure 2. (A) Serum triglyceride levels in SCID/CID, FHL, I-HLH, and CGD patients. (B) Serum fibrinogen levels in SCID/CID, FHL, I-HLH, and CGD
patients. *P<0.05.  The dotted line indicates the cut-off value according to the HLH diagnostic criteria. The bars indicate means ± standard
deviation.
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